195.42 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||195.99 x 3100|
|Ask||195.40 x 1100|
|Day's Range||189.55 - 196.21|
|52 Week Range||154.52 - 247.64|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||39.64|
|Earnings Date||Apr 20, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||248.15|
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced 2-year results of the randomized PARTNER 3 trial comparing treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe.
Edwards Lifesciences, The Trade Desk, Blue Apron, Domino's Pizza and Grubhub highlighted as Zacks Bull and Bear of the Day
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.
A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?
Health care, which makes up nearly 18% of American GDP, has long been a fruitful hunting ground for investors seeking growth. And medical-tech and medical-device stocks have always been particularly compelling niches.Not only do these companies ride the coattails of inexorable health-care spending, but their commitment to research and development can create new industries that they can in turn dominate.It's not an easy time right now, of course. The COVID-19 outbreak has taken a chunk out of every sector and almost every industry, with only a few "coronavirus stocks" enjoying any meaningful gains. Medical devices have at least been better than the market, which has declined by about 29% in this bear market so far, as measured by the S&P; 500\. But the iShares U.S. Medical Devices ETF (IHI) still has been cut to the tune of 25% in the same time frame.That could provide investors with a chance to buy medical-device stocks and other med-tech plays at a significant discount, however. While their growth might be stunted in the short-term, their longer-term prospects are likely to improve again once the COVID-19 threat is contained - and a few are seeing additional business in the wake of the outbreak.Here, we look at six med-tech and medical-device stocks to buy. SEE ALSO: 10 Health and Pharmaceutical Companies Fighting the Coronavirus
Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Some of the largest health care stocks in the world include Johnson & Johnson (JNJ) and Pfizer, Inc. (PFE).
Some hospitals in the U.S. are already canceling or postponing elective medical appointments and procedures as they prepare for the possibility of a surge in COVID-19 patients.
Edwards Lifesciences Corporation (NYSE:EW) received a lot of attention from a substantial price movement on the NYSE...
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Edwards Lifesciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 77 to 81. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Edwards Lifesciences...
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to present at the Cowen Healthcare Conference at the Boston Marriott Copley Place on Monday, March 2, 2020.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced a new goal for its philanthropic initiative, Every Heartbeat Matters (EHM): to improve the lives of 2.5 million additional underserved structural heart and critical care patients by the end of 2025.
Edwards Lifesciences (EW) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Call it the democratization of the echocardiogram — as this young company's software enables more medical professionals to use the heart-image technology, it looks to nearly double staff in the next year.